CreativeOne Wealth LLC Buys Shares of 7,837 Exelixis, Inc. (NASDAQ:EXEL)

CreativeOne Wealth LLC bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, HoldingsChannel reports. The fund bought 7,837 shares of the biotechnology company’s stock, valued at approximately $203,000.

Several other institutional investors have also recently added to or reduced their stakes in EXEL. V Square Quantitative Management LLC bought a new stake in Exelixis during the third quarter valued at $30,000. Brooklyn Investment Group bought a new stake in Exelixis during the third quarter valued at $42,000. GAMMA Investing LLC increased its stake in Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares during the last quarter. Capital Performance Advisors LLP bought a new stake in Exelixis during the third quarter valued at $61,000. Finally, Essex Investment Management Co. LLC bought a new stake in Exelixis during the third quarter valued at $74,000. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on EXEL shares. Stifel Nicolaus boosted their price target on shares of Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and set a $29.00 price target on shares of Exelixis in a report on Wednesday, September 18th. Bank of America boosted their price target on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Royal Bank of Canada reissued an “outperform” rating and set a $34.00 price target on shares of Exelixis in a report on Wednesday, October 30th. Finally, Wells Fargo & Company boosted their price target on shares of Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.44.

Insiders Place Their Bets

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $26.38, for a total transaction of $659,500.00. Following the sale, the executive vice president now owns 605,325 shares in the company, valued at approximately $15,968,473.50. The trade was a 3.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Dana Aftab sold 96,986 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the sale, the executive vice president now owns 498,945 shares in the company, valued at approximately $17,463,075. The trade was a 16.27 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 339,736 shares of company stock worth $11,508,610. Company insiders own 2.85% of the company’s stock.

Exelixis Trading Down 0.9 %

Shares of Exelixis stock opened at $35.26 on Wednesday. The company’s 50-day moving average price is $31.00 and its two-hundred day moving average price is $26.25. Exelixis, Inc. has a 52 week low of $19.20 and a 52 week high of $36.97. The stock has a market cap of $10.07 billion, a PE ratio of 22.60, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the previous year, the business earned $0.10 earnings per share. Exelixis’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, equities analysts predict that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.